Fulcrum Therapeutics vs Septerna
FULC and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FULC and SEPN compare
Septerna is the larger company, worth 6.9 times as much as Fulcrum Therapeutics ($2.0B against $288M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FULC | SEPN |
|---|---|---|
| Size and price | ||
| Market cap | $288M | $2.0B |
| Share price | $3.77 | $42.60 |
| Change, 1 year | −54.9% | 122% |
| Change, 5 years | −78.0% | – |
| Beta (5Y) | 1.56 | 1.87 |
| Employees | 55 | 130 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 20.7× |
| P/B | 1.0× (better) | 4.6× |
| FCF yield | −22.7% | −3.9% (better) |
| Fair value | – | $14.45 |
| Margin of safety | – | −195% |
| Growth | ||
| Revenue growth (TTM) | – | 337% |
| Profitability | ||
| Operating margin | – | −76.2% |
| Net margin | – | −61.3% |
| FCF margin | – | −80.6% |
| Return on equity | −30.5% | −14.4% (better) |
| Return on invested capital | −41.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 36.19 (better) | 4.84 |
| Altman Z-score | 16.95 (better) | 6.29 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 102% |
| Held by insiders | 34.7% | 28.1% |
| Insider net buying, 12 months | −$57.5M (better) | −$76.1M |
| Short interest, % of float | 12.9% | 10.0% |
Go deeper
- FULC stock overview
- FULC income statement
- FULC valuation and score
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.